Lutz Buellesfeld

Summary

Affiliation: HELIOS Klinikum Wuppertal
Country: Germany

Publications

  1. ncbi Percutaneous implantation of the first repositionable aortic valve prosthesis in a patient with severe aortic stenosis
    Lutz Buellesfeld
    Department of Cardiology, HELIOS Heart Center Siegburg, Siegburg, Germany
    Catheter Cardiovasc Interv 71:579-84. 2008
  2. ncbi "Device landing zone" calcification, assessed by MSCT, as a predictive factor for pacemaker implantation after TAVI
    George Latsios
    Department of Cardiology, HELIOS Heart Center Siegburg, Siegburg, Germany
    Catheter Cardiovasc Interv 76:431-9. 2010
  3. ncbi Progress and current status of percutaneous aortic valve replacement: results of three device generations of the CoreValve Revalving system
    Eberhard Grube
    Departments of Cardiology, Cardiac Surgery, and Anaesthesiology, HELIOS Heart Center Siegburg, Ringstrasse 49, Siegburg, Germany
    Circ Cardiovasc Interv 1:167-75. 2008
  4. ncbi Percutaneous implantation of the CoreValve self-expanding valve prosthesis in high-risk patients with aortic valve disease: the Siegburg first-in-man study
    Eberhard Grube
    Department of Cardiology Angiology, HELIOS Heart Center Siegburg, Ringstrasse 49, 53721 Siegburg, Germany
    Circulation 114:1616-24. 2006
  5. ncbi Evaluation of a new polymer-coated paclitaxel-eluting stent for treatment of de novo lesions: six-month clinical and angiographic follow-up results of the APPLAUSE trial
    Eberhard Grube
    Department of Cardiology and Angiology, Heart Center, Siegburg, Germany
    J Invasive Cardiol 18:194-8. 2006
  6. ncbi Transcatheter aortic valve implantation: predictors of procedural success--the Siegburg-Bern experience
    Lutz Buellesfeld
    Department of Cardiology Angiology, HELIOS Heart Center Siegburg, Ringstrasse 49, 53721 Siegburg, Germany
    Eur Heart J 31:984-91. 2010
  7. ncbi Use of Taxus polymer-coated paclitaxel-eluting stents for treatment of in-stent restenosis in real world patients: results of clinical and angiographic follow-up at six months in a single-center registry
    Victor Y Lim
    Department of Cardiology and Angiology, HELIOS Heart Center Siegburg, Siegburg, Germany
    Catheter Cardiovasc Interv 68:343-8. 2006
  8. ncbi Correlation of Device landing zone calcification and acute procedural success in patients undergoing transcatheter aortic valve implantations with the self-expanding CoreValve prosthesis
    Daniel John
    Department of Cardiology Angiology, HELIOS Heart Center Siegburg, Siegburg, Germany
    JACC Cardiovasc Interv 3:233-43. 2010
  9. ncbi Procedural and mid-term results in patients with aortic stenosis treated with implantation of 2 (in-series) CoreValve prostheses in 1 procedure
    Ulrich Gerckens
    Department of Cardiology Angiology, HELIOS Heart Center, Siegburg, Germany
    JACC Cardiovasc Interv 3:244-50. 2010
  10. ncbi Percutaneous aortic valve replacement for severe aortic regurgitation in degenerated bioprosthesis: the first valve in valve procedure using the Corevalve Revalving system
    Peter Wenaweser
    Department of Cardiology Angiology, HELIOS Heart Center Siegburg, Siegburg, Germany
    Catheter Cardiovasc Interv 70:760-4. 2007

Detail Information

Publications29

  1. ncbi Percutaneous implantation of the first repositionable aortic valve prosthesis in a patient with severe aortic stenosis
    Lutz Buellesfeld
    Department of Cardiology, HELIOS Heart Center Siegburg, Siegburg, Germany
    Catheter Cardiovasc Interv 71:579-84. 2008
    ..We implanted this prosthesis in a 93-year old patient presenting with severe symptomatic aortic stenosis (valve area: 0.6 cm(2)). Surgical valve replacement had been declined due to comorbidities...
  2. ncbi "Device landing zone" calcification, assessed by MSCT, as a predictive factor for pacemaker implantation after TAVI
    George Latsios
    Department of Cardiology, HELIOS Heart Center Siegburg, Siegburg, Germany
    Catheter Cardiovasc Interv 76:431-9. 2010
    ..The aim of this study was to assess the possible predictive factors of post TAVI PM implantation based on Computed Tomography (CT) measured aortic valve calcification and its distribution...
  3. ncbi Progress and current status of percutaneous aortic valve replacement: results of three device generations of the CoreValve Revalving system
    Eberhard Grube
    Departments of Cardiology, Cardiac Surgery, and Anaesthesiology, HELIOS Heart Center Siegburg, Ringstrasse 49, Siegburg, Germany
    Circ Cardiovasc Interv 1:167-75. 2008
    ..This study was intended to provide a summary of the development and current safety and efficacy status of the self-expanding CoreValve Revalving prosthesis...
  4. ncbi Percutaneous implantation of the CoreValve self-expanding valve prosthesis in high-risk patients with aortic valve disease: the Siegburg first-in-man study
    Eberhard Grube
    Department of Cardiology Angiology, HELIOS Heart Center Siegburg, Ringstrasse 49, 53721 Siegburg, Germany
    Circulation 114:1616-24. 2006
    ....
  5. ncbi Evaluation of a new polymer-coated paclitaxel-eluting stent for treatment of de novo lesions: six-month clinical and angiographic follow-up results of the APPLAUSE trial
    Eberhard Grube
    Department of Cardiology and Angiology, Heart Center, Siegburg, Germany
    J Invasive Cardiol 18:194-8. 2006
    ....
  6. ncbi Transcatheter aortic valve implantation: predictors of procedural success--the Siegburg-Bern experience
    Lutz Buellesfeld
    Department of Cardiology Angiology, HELIOS Heart Center Siegburg, Ringstrasse 49, 53721 Siegburg, Germany
    Eur Heart J 31:984-91. 2010
    ..The purpose of the present analysis was to identify predictors of procedural success of percutaneous transcatheter aortic valve implantation (TAVI)...
  7. ncbi Use of Taxus polymer-coated paclitaxel-eluting stents for treatment of in-stent restenosis in real world patients: results of clinical and angiographic follow-up at six months in a single-center registry
    Victor Y Lim
    Department of Cardiology and Angiology, HELIOS Heart Center Siegburg, Siegburg, Germany
    Catheter Cardiovasc Interv 68:343-8. 2006
    ..1%) at 3 days after intervention. CONCLUSIONS: Paclitaxel-eluting Taxus stent for the treatment of ISR effectively suppresses recurrent neointimal proliferation, and was safe and efficacious at 6-month follow-up...
  8. ncbi Correlation of Device landing zone calcification and acute procedural success in patients undergoing transcatheter aortic valve implantations with the self-expanding CoreValve prosthesis
    Daniel John
    Department of Cardiology Angiology, HELIOS Heart Center Siegburg, Siegburg, Germany
    JACC Cardiovasc Interv 3:233-43. 2010
    ....
  9. ncbi Procedural and mid-term results in patients with aortic stenosis treated with implantation of 2 (in-series) CoreValve prostheses in 1 procedure
    Ulrich Gerckens
    Department of Cardiology Angiology, HELIOS Heart Center, Siegburg, Germany
    JACC Cardiovasc Interv 3:244-50. 2010
    ..This study sought to assess post-procedural and mid-term outcome of patients, in which a second "in-series" CoreValve prosthesis (Medtronic, Minneapolis, Minnesota) was implanted during the same procedure...
  10. ncbi Percutaneous aortic valve replacement for severe aortic regurgitation in degenerated bioprosthesis: the first valve in valve procedure using the Corevalve Revalving system
    Peter Wenaweser
    Department of Cardiology Angiology, HELIOS Heart Center Siegburg, Siegburg, Germany
    Catheter Cardiovasc Interv 70:760-4. 2007
    ..We report on the first successful valve in valve procedure in an 80-year-old patient with a severe regurgitation of a degenerated aortic bioprosthesis using the Corevalve Revalving system...
  11. ncbi Polymer-based paclitaxel-eluting stent for treatment of chronic total occlusions of native coronaries: results of a Taxus CTO registry
    Lutz Buellesfeld
    Heart Center Siegburg, Siegburg, Germany
    Catheter Cardiovasc Interv 66:173-7. 2005
    ..The quantitative angiographic analysis revealed beneficial results with respect to the efficacy surrogates binary restenosis rate and late loss...
  12. ncbi Two-year-plus follow-up of a paclitaxel-eluting stent in de novo coronary narrowings (TAXUS I)
    Eberhard Grube
    Heart Center Siegburg, Siegburg, Germany
    Am J Cardiol 96:79-82. 2005
    ..The single target vessel revascularization in the TAXUS group was remote from the target lesion in contrast to 3 target lesion revascularizations in the control group...
  13. ncbi Percutaneous aortic valve replacement for severe aortic stenosis in high-risk patients using the second- and current third-generation self-expanding CoreValve prosthesis: device success and 30-day clinical outcome
    Eberhard Grube
    HELIOS Heart Center Siegburg, Siegburg, Germany
    J Am Coll Cardiol 50:69-76. 2007
    ..We sought to determine both the procedural performance and safety of percutaneous implantation of the second (21-French [F])- and third (18-F)-generation CoreValve aortic valve prosthesis (CoreValve Inc., Irvine, California)...
  14. ncbi TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions
    Eberhard Grube
    Department of Cardiology Angiology, Heart Center Siegburg, Siegburg, Germany
    Circulation 107:38-42. 2003
    ..The TAXUS I trial was the first in-human experience evaluating safety and feasibility of the TAXUS NIRx stent system compared with bare NIR stents (control) (Boston Scientific Corp) for treatment of coronary lesions...
  15. ncbi Novel drug eluting stent system for customised treatment of coronary lesions: CUSTOM I feasibility trial 24 month results
    Eberhard Grube
    Department of Cardiology Angiology, HELIOS Heart Center Siegburg, Siegburg, Germany
    EuroIntervention 4:71-6. 2008
    ....
  16. ncbi BioMatrix Biolimus A9-eluting coronary stent: a next-generation drug-eluting stent for coronary artery disease
    Eberhard Grube
    HELIOS Heart Center Siegburg, Department of Cardiology Angiology, Ringstrasse 49, 53721 Siegburg, Germany
    Expert Rev Med Devices 3:731-41. 2006
    ..Clinical studies have demonstrated the BioMatrix to be well tolerated and effective, and it has now become the subject of an aggressive clinical program...
  17. ncbi Six-month clinical and angiographic results of a dedicated drug-eluting stent for the treatment of coronary bifurcation narrowings
    Eberhard Grube
    HELIOS Heart Center, Siegburg, Germany
    Am J Cardiol 99:1691-7. 2007
    ..In conclusion, the Axxess Plus conical stent effectively treats bifurcation lesions alone or in conjunction with other drug-eluting stents...
  18. ncbi High-frequency mechanical vibration to recanalize chronic total occlusions after failure to cross with conventional guidewires
    Eberhard Grube
    Klinikum Siegburg, Siegburg, Germany
    J Invasive Cardiol 18:85-91. 2006
    ..CONCLUSIONS: The CROSSER system is a safe device that can cross many occlusions after a conventional guidewire failure. With additional refinement and improvements to the device, this success rate could be further increased...
  19. ncbi TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions
    Eberhard Grube
    HELIOS Heart Center Siegburg, Siegburg, Germany
    Eur Heart J 28:2578-82. 2007
    ..In order to assess the long-term safety and clinical efficacy of the polymer-based moderate release (MR) paclitaxel-eluting TAXUS MR stent in treatment of complex lesion subsets, we evaluated the 2-year follow-up of TAXUS VI...
  20. ncbi Images in cardiovascular medicine. Intracoronary imaging with optical coherence tomography: a new high-resolution technology providing striking visualization in the coronary artery
    Eberhard Grube
    Department of Cardiology/Angiology, Heart-Center Siegburg, Siegburg, Germany
    Circulation 106:2409-10. 2002
  21. ncbi Optical Coherence Tomography (OCT). Potential of a new high-resolution intracoronary imaging technique
    Ulrich Gerckens
    Department of Cardiology Angiology, Heart Center, Klinikum Siegburg Rhein Sieg GmbH, Siegburg, Germany
    Herz 28:496-500. 2003
    ....
  22. ncbi First report on a human percutaneous transluminal implantation of a self-expanding valve prosthesis for interventional treatment of aortic valve stenosis
    Eberhard Grube
    Department of Cardiology, Heart Center Siegburg, Siegburg, Germany
    Catheter Cardiovasc Interv 66:465-9. 2005
    ..7 cm2). Surgical valve replacement had been declined for the patient because of comorbidities, including previous bypass surgery...
  23. ncbi Computerized two-lead resting ECG analysis for the detection of coronary artery stenosis after coronary revascularization
    Eberhard Grube
    Department of Cardiology, Angiology, HELIOS Heart Center Siegburg, Siegburg, Germany
    Int J Med Sci 5:50-61. 2008
    ..We compared a new computer-enhanced, resting ECG analysis device, 3DMP, to coronary angiography to evaluate the device's accuracy in detecting hemodynamically relevant CAD...
  24. ncbi Paclitaxel-eluting stents: current clinical experience
    Eberhard Grube
    Heart Center Siegburg, Siegburg, Germany
    Am J Cardiovasc Drugs 4:355-60. 2004
    ..Programs like these are vital to sufficiently monitor patients who have received a drug-eluting stent, particularly because of the controversy regarding long-term effects...
  25. ncbi Everolimus for stent-based intracoronary applications
    Eberhard Grube
    Heart-Center Siegburg, Siegburg, Germany
    Rev Cardiovasc Med 5:S3-8. 2004
    ..The everolimus-eluting coronary stent might shortly be established as a new and promising contender in the field of drug eluting stents for treatment of coronary heart disease...
  26. ncbi Results of the Jostent coronary stent graft implantation in various clinical settings: procedural and follow-up results
    Ulrich Gercken
    Department of Cardiology and Angiology, Heart-Center, Siegburg, Siegburg, Germany
    Catheter Cardiovasc Interv 56:353-60. 2002
    ..Covered stents such as the JoMed coronary stent graft may become essential for bailout treatment of coronary perforations...
  27. ncbi [Percutaneous aortic valve replacement]
    Eberhard Grube
    Medizinische Klinik Kardiologie und Angiologie, HELIOS Klinikum Siegburg, Ringstrasse 49, 53721 Siegburg
    Herz 31:694-7. 2006
    ..However, the strict inclusion criteria for both procedures limit the number of potential candidates. New devices are currently under development, which will allow for a broader use of percutaneous valve replacement in the near future...
  28. ncbi Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents
    Eberhard Grube
    Department of Cardiology Angiology, Heart Center Siegburg, Germany
    Herz 29:162-6. 2004
    ....
  29. ncbi ABT-578-eluting stents. The promising successor of sirolimus- and paclitaxel-eluting stent concepts?
    Lutz Buellesfeld
    Department of Cardiology Angiology, Heart Center Siegburg, Germany
    Herz 29:167-70. 2004
    ..If the results of both pivotal studies ENDEAVOR II and III confirm the efficacy of the ENDEAVOR stent design observed so far, the ENDEAVOR stent will be established as a new and promising contender in the field of DES...